SCHEMBL5550889

SCHEMBL5550889

Cc1ccc(C(N)=O)c(Cc2ccccc2)c1Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 9/20 0.47
PLA2G10 O15496 8/20 0.47
IDH1 O75874 1/20 0.46
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ADRA1D P25100 2/20 0.41
PLA2G1B P04054 1/20 0.40
PLA2G5 P39877 1/20 0.40
PLA2G2C Q5R387 1/20 0.40
PLA2G12B Q9BX93 1/20 0.40
PLA2G12A Q9BZM1 1/20 0.40
PLA2G2F Q9BZM2 1/20 0.40
PLA2G3 Q9NZ20 1/20 0.40
PLA2G2E Q9NZK7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28681774 0.89 PLA2G2A (0.57) PLA2G2APLA2G10USP2ALDH1A1MAPT
SCHEMBL5482150 0.86 PLA2G2A (0.45) PLA2G2APLA2G10IDH1USP2ALDH1A1
SCHEMBL6528867 0.83 ALDH1A1 (0.42) PLA2G2APLA2G10IDH1USP2ALDH1A1
SCHEMBL10318607 0.81 ALDH1A1 (0.44) PLA2G2APLA2G10IDH1USP2ALDH1A1
SCHEMBL28778955 0.80 PLA2G2A (0.47) PLA2G2APLA2G10USP2ALDH1A1MAPT
SCHEMBL28778944 0.80 MAPT (0.48) PLA2G2APLA2G10ALDH1A1MAPTHPGD
SCHEMBL4937860 0.80 PLA2G2A (0.44) PLA2G2APLA2G10IDH1USP2ALDH1A1
SCHEMBL5482149 0.78 MYC (0.47) PLA2G2APLA2G10IDH1USP2ALDH1A1
SCHEMBL7204828 0.78 IDH1 (0.47) IDH1ALDH1A1HTTLMNA
SCHEMBL2326693 0.78 PLA2G2A (0.45) PLA2G2APLA2G10IDH1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1862181-A2 Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders NOVO NORDISK A/S (DK) 2007-12-05 EP claimed
CN-111039813-B Synthetic method of aromatic amide compound 江南大学 2022-07-01 CN disclosed
CN-111039813-A Synthetic method of aromatic amide compound 江南大学 2020-04-21 CN disclosed
EP-1862181-A2 Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders NOVO NORDISK A/S (DK) 2007-12-05 EP disclosed
EP-1854487-A2 Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist Novo Nordisk A/S (DK) 2007-11-14 EP disclosed